Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
Ann Rheum Dis. 10 May 2015 doi:10.1136/annrheumdis-2015-207281 [Epub ahead of print]
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis. 10 May 2015 doi:10.1136/annrheumdis-2015-207281 [Epub ahead of print]
J Am Acad Dermatol 2015;73:37-49. doi: 10.1016/j.jaad.2015.03.049
Here, investigators reported that efficacy measures for skin and scalp were significantly greater for apremilast than for placebo in patients with PsO at baseline. Previously, clinical study data has highlighted that the use of apremilast leads to a reduction in the expression within the epidermis of numerous inflammatory cytokines relevant to PsO. As a result, ESTEEM 1 evaluated the efficacy/safety of apremilast at 30 mg BID for moderate to severe PsO.
Arthritis Rheumatol. 2015 May 4. doi: 10.1002/art.39183. [Epub ahead of print]
Ann Rheum Dis. 2015 Apr 22. pii: annrheumdis-2014-205847. doi: 10.1136/annrheumdis-2014-205847. [Epub ahead of print]
Nature. 2015 Feb 16. doi: 10.1038/nature14154. [Epub ahead of print]
Arthritis Rheumatol. Vol. 67, No. 6, June 2015, pp 1424–1437
Ann Rheum Dis. 2015 Mar 20. pii: annrheumdis-2014-207191. doi: 10.1136/annrheumdis-2014-207191. [Epub ahead of print]
Arthritis Rheumatol. 2015;67(2):334–343.
Nat Med. 2015 Feb 16. doi: 10.1038/nm.3806. [Epub ahead of print]
Arthritis Rheumatol. 2015;67(3):616-25.